Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.

about

Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.

Item

http://www.wikidata.org/entity/Q36030323

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Increased Biological Effective ...... g Cancer: A Systematic Review.

@ast

Increased Biological Effective ...... g Cancer: A Systematic Review.

@en

type

Item

label

Increased Biological Effective ...... g Cancer: A Systematic Review.

@ast

Increased Biological Effective ...... g Cancer: A Systematic Review.

@en

prefLabel

Increased Biological Effective ...... g Cancer: A Systematic Review.

@ast

Increased Biological Effective ...... g Cancer: A Systematic Review.

@en

P1476

Increased Biological Effective ...... g Cancer: A Systematic Review.

@en

P2093

Bing Wang

http://www.w3.org/2001/XMLSchema#string

Bing Xia

http://www.w3.org/2001/XMLSchema#string

Kan Wu

http://www.w3.org/2001/XMLSchema#string

Qinghua Deng

http://www.w3.org/2001/XMLSchema#string

Shenglin Ma

http://www.w3.org/2001/XMLSchema#string

Shirong Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao Xu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Staging and clinical prognostic factors for small-cell lung cancer.

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.

Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

The role of biologically effective dose (BED) in clinical oncology.

Biological factors influencing optimum fractionation in radiation therapy.

The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer.

Radiation dose escalation in limited-stage small-cell lung cancer.

P304

e0156494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1371/JOURNAL.PONE.0156494

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucheng Zhu

P5008

ScienceSource

P577

2016-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27227819

http://www.w3.org/2001/XMLSchema#string

P921

lung small cell carcinoma

lung cancer

P932

4882048

http://www.w3.org/2001/XMLSchema#string